Patents Assigned to Daiichi Sankyo Company, Limited
  • Patent number: 10973924
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 13, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Patent number: 10975052
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: April 13, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10968169
    Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 6, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
  • Patent number: 10961240
    Abstract: Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: March 30, 2021
    Assignees: Plexxikon Inc., Daiichi Sankyo Company, Limited
    Inventors: Prabha N. Ibrahim, Hamid Rezaei, Gary Conard Visor, Tomoari Kamo, Hiroshi Yamakose
  • Publication number: 20210087560
    Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.
    Type: Application
    Filed: February 6, 2019
    Publication date: March 25, 2021
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Inoue, Heng Li, Takashi Okada, Yu Ohki, Makoto Koizumi
  • Patent number: 10954219
    Abstract: The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: March 23, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Osamu Kanno, Jun Watanabe, Takao Horiuchi, Akira Nakao, Keisuke Suzuki, Tomonori Yamasaki, Nobuaki Adachi, Daisuke Honma, Yoshito Hamada
  • Patent number: 10947289
    Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: March 16, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mitsuhiro Iwamoto, Takahiro Yamaguchi, Yutaka Mori, Keiji Saito, Takeshi Honda, Takahiro Nagayama
  • Publication number: 20210053965
    Abstract: It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: February 25, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Toshihiro Kiho, Tatsuya Yano, Satoshi Komoriya, Taisaku Tanaka
  • Patent number: 10925848
    Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. Provided is a pharmaceutical composition containing, as an active ingredient, a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula (I), R1 and R2 are the same or different, and represent a C1-C6 alkyl group, a halogeno C1-C6 alkyl group or a C3-C6 cycloalkyl group; n represents 0, 1 or 2; each X represents a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a halogen atom or the like; and Y represents a hydrogen atom, a C1-C6 alkoxy group, a C3-C6 cycloalkoxy group or a halogeno C1-C6 alkoxy group.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 23, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Soneda, Hiroki Sakai, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
  • Patent number: 10918671
    Abstract: The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. To solve this problem, the present inventors studied the possibility of constructing cell masses from the purified cardiomyocytes. As a result, they revealed that the stated problem could be solved by providing a method of preparing cell masses of cardiomyocytes derived from pluripotent stem cells, characterized in that cell masses of aggregated cells containing cardiomyocytes that had been differentiated and induced from pluripotent stem cells were dispersed to single cells to thereby obtain purified cardiomyocytes, which were then cultured in a culture medium under serum-free conditions so that they were reaggregated.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 16, 2021
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, HEARTSEED INC.
    Inventors: Fumiyuki Hattori, Keiichi Fukuda
  • Publication number: 20210040170
    Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mitsuhiro IWAMOTO, Takahiro YAMAGUCHI, Yutaka MORI, Keiji SAITO, Takeshi HONDA, Takahiro NAGAYAMA
  • Publication number: 20210040057
    Abstract: The present invention directs to provide a novel compound for treating and/or preventing pain, having excellent skin permeation and reduced skin irritation.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 11, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventor: Keisuke Suzuki
  • Publication number: 20210040225
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: October 13, 2020
    Publication date: February 11, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20210032313
    Abstract: Provided is a novel peptide. The peptide contains the amino acid sequence set forth in SEQ ID NO: 61 and inhibits a protease.
    Type: Application
    Filed: October 6, 2020
    Publication date: February 4, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • Patent number: 10906974
    Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: February 2, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji Iida, Takehiro Hirai, Tomoko Terauchi, Kensuke Nakamura
  • Publication number: 20210024520
    Abstract: The present invention has an object of providing a pharmaceutical drug containing a compound having a good LCAT activation effect on a mutant LCAT protein and a therapeutic effect for LCAT deficiency, and also provides a therapeutic drug for LCAT deficiency containing a compound represented by Formula (I) wherein R1 is a hydrogen atom or a hydroxyl group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 26, 2019
    Publication date: January 28, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuhiro Sugidachi, Keisuke Yamada
  • Publication number: 20210009709
    Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 14, 2021
    Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takenobu KATAGIRI, Sho TSUKAMOTO, Keigo KUMAGAI, Shinnosuke TSUJI
  • Publication number: 20210008069
    Abstract: The present invention aims to provide a pharmaceutical drug that contains a compound having an excellent therapeutic effect on inflammatory bowel disease. A therapeutic agent for inflammatory bowel disease, containing as an active ingredient a compound represented by formula (I), wherein R1 represents a hydroxy C1-C6 alkyl group, a C2-C7 alkanoyl group, a C2-C7 alkanoyl C1-C6 alkyl group, a (C1-C6 alkoxy) carbonyl group, a (C1-C6 alkoxy) carbonyl C1-C6 alkyl group, a carboxy group or a carboxy C1-C6 alkyl group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2019
    Publication date: January 14, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Yuki TOYOSHIMA
  • Patent number: 10881734
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 5, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • Publication number: 20200407394
    Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to the cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648G>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takeshi MASUDA, Mitsuhiro IWAMOTO, Yukiko SEKIGUCHI, Kentaro ITO, Shinnosuke TSUJI, Masafumi MATSUO